An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

NCT ID: NCT01333007

Last Updated: 2016-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

423 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Squamous Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \>/= 18 years of age
* Inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
* Treating physician's decision to initiate first-line Avastin treatment

Exclusion Criteria

* Participation in a clinical trial evaluating anti-cancer therapies
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Abbeville, , France

Site Status

Agen, , France

Site Status

Aix-en-Provence, , France

Site Status

Aix-en-Provence, , France

Site Status

Alès, , France

Site Status

Ambilly, , France

Site Status

Amiens, , France

Site Status

Amilly, , France

Site Status

Angers, , France

Site Status

Annecy, , France

Site Status

Antibes, , France

Site Status

Armentières, , France

Site Status

Arras, , France

Site Status

Aubenas, , France

Site Status

Aulnay-sous-Bois, , France

Site Status

Auxerre, , France

Site Status

Bar-le-Duc, , France

Site Status

Bastia, , France

Site Status

Bastia, , France

Site Status

Bayeux, , France

Site Status

Bayonne, , France

Site Status

Bayonne, , France

Site Status

Besançon, , France

Site Status

Beuvry, , France

Site Status

Biarritz, , France

Site Status

Bobigny, , France

Site Status

Bois-Guillaume, , France

Site Status

Bordeaux, , France

Site Status

Bordeaux, , France

Site Status

Boulogne-sur-Mer, , France

Site Status

Bourg-en-Bresse, , France

Site Status

Brest, , France

Site Status

Brest, , France

Site Status

Brive-la-Gaillarde, , France

Site Status

Bron, , France

Site Status

Bry-sur-Marne, , France

Site Status

Caen, , France

Site Status

Cagnes-sur-Mer, , France

Site Status

Cahors, , France

Site Status

Carcassonne, , France

Site Status

Chalon-sur-Saône, , France

Site Status

Chambray-lès-Tours, , France

Site Status

Charleville-Mézières, , France

Site Status

Chaumont, , France

Site Status

Chauny, , France

Site Status

Châteauroux, , France

Site Status

Cherbourg Octeville, , France

Site Status

Clamart, , France

Site Status

Clermont-Ferrand, , France

Site Status

Colmar, , France

Site Status

Compiègne, , France

Site Status

Compiègne, , France

Site Status

Cornebarrieu, , France

Site Status

Creil, , France

Site Status

Créteil, , France

Site Status

Dax, , France

Site Status

Dijon, , France

Site Status

Dunkirk, , France

Site Status

Eaubonne, , France

Site Status

Épernay, , France

Site Status

Évreux, , France

Site Status

Fontainebleau, , France

Site Status

Gap, , France

Site Status

Gleizé, , France

Site Status

Granville, , France

Site Status

Hyères, , France

Site Status

La Chaussée-Saint-Victor, , France

Site Status

La Roche-sur-Yon, , France

Site Status

La Seyne-sur-Mer, , France

Site Status

La Source, , France

Site Status

Le Mans, , France

Site Status

Le Perreux-sur-Marne, , France

Site Status

Levallois-Perret, , France

Site Status

Libourne, , France

Site Status

Liévin, , France

Site Status

Lille, , France

Site Status

Lille, , France

Site Status

Limoges, , France

Site Status

Longjumeau, , France

Site Status

Lorient, , France

Site Status

Lormont, , France

Site Status

Lyon, , France

Site Status

Lyon, , France

Site Status

Lyon, , France

Site Status

Lyon, , France

Site Status

Lyon, , France

Site Status

Mareuil-lès-Meaux, , France

Site Status

Marseille, , France

Site Status

Maubeuge, , France

Site Status

Meaux, , France

Site Status

Metz, , France

Site Status

Metz-Tessy, , France

Site Status

Mont-de-Marsan, , France

Site Status

Montauban, , France

Site Status

Montélimar, , France

Site Status

Montfermeil, , France

Site Status

Montpellier, , France

Site Status

Mulhouse, , France

Site Status

Nancy, , France

Site Status

Narbonne, , France

Site Status

Nemours, , France

Site Status

Neuilly-sur-Seine, , France

Site Status

Nevers, , France

Site Status

Osny, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Pau, , France

Site Status

Perpignan, , France

Site Status

Pierre-Bénite, , France

Site Status

Pontarlier, , France

Site Status

Pontoise, , France

Site Status

Rambouillet, , France

Site Status

Reims, , France

Site Status

Reims, , France

Site Status

Reims, , France

Site Status

Rennes, , France

Site Status

Rouen, , France

Site Status

Rouen, , France

Site Status

Saint-Aubin-lès-Elbeuf, , France

Site Status

Saint-Herblain, , France

Site Status

Saint-Jean, , France

Site Status

Saint-Lô, , France

Site Status

Saint-Priest-en-Jarez, , France

Site Status

Saint-Quentin, , France

Site Status

Saintes, , France

Site Status

Senlis, , France

Site Status

Soissons, , France

Site Status

Ste Feyre, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Tarbes, , France

Site Status

Thionville, , France

Site Status

Thonon-les-Bains, , France

Site Status

Toulon, , France

Site Status

Toulon, , France

Site Status

Toulouse, , France

Site Status

Vandœuvre-lès-Nancy, , France

Site Status

Vannes, , France

Site Status

Vannes, , France

Site Status

Verdun, , France

Site Status

Versailles, , France

Site Status

Vesoul, , France

Site Status

Vénissieux, , France

Site Status

Vichy, , France

Site Status

Villeneuve-Saint-Georges, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML22991

Identifier Type: -

Identifier Source: org_study_id